RenovoRx (RNXT) 2026 proxy: board elections, equity pool increase and auditor vote
RenovoRx, Inc. (RNXT) has issued its 2026 proxy statement detailing proposals for its Annual Meeting on June 30, 2026. Stockholders will vote on electing six directors, increasing the shares available under the 2021 Omnibus Equity Incentive Plan by 2,000,000 (4.4% of total outstanding shares), and ratifying Frank, Rimerman + Co. LLP as the independent registered public accounting firm for 2026. The proxy also outlines executive compensation for 2025, with CEO Shaun R. Bagai receiving over $1.2 million, and provides details on the company's board structure, committee responsibilities, and director independence.
MAR 31·Stock Titan▲
Cancer device reaches 12 U.S. centers as RenovoRx readies trial finish
RenovoRx reported full-year 2025 revenue of $1.1 million for its RenovoCath device, a significant increase from 2024, with 12 U.S. cancer centers actively utilizing the device and 21 more evaluating it. The company's Phase III TIGeR-PaC trial is on track for enrollment completion by mid-2026, with final data anticipated in 2027. RenovoRx also strengthened its financial position with a $10 million private placement, bringing its cash on hand to approximately $13 million.
NOV 19·Benzinga▲
RenovoRx CEO Shaun Bagai to Present at the Alliance Global Partners Emerging AgBiotech/Bio-Solutions Virtual Showcase on November 20th - RenovoRx ( NASDAQ:RNXT )
MOUNTAIN VIEW, Calif., Nov. 19, 2025 ( GLOBE NEWSWIRE ) -- RenovoRx, Inc. ( NASDAQ:RNXT ) ( "RenovoRx" or "the Company" ) , a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath®, a novel, FDA-cleared drug-delivery device, today announced that ...
